A new drug for the treatment of attention deficit hyperactivity disorder (ADHD) will be listed from 1 July 2007 on the Pharmaceutical Benefits Scheme (PBS).
The drug, Strattera? (atomoxetine), will provide treatment for children between the ages of six and 18 years who cannot take stimulants.
ADHD is a behavioural and developmental disorder that affect young children. The main symptoms of ADHD ? inattention, hyperactivity and impulsivity ? contribute to adverse academic and social behaviour, which can have consequences that persist throughout adolescence and into adulthood.
Treatment for ADHD normally involves stimulant therapy, so the listing of Strattera? on the PBS will especially benefit those who are unable to take stimulants.
About 18,000 people will commence Strattera? in the first full financial year of listing.
The listing of Strattera? will add around $101.2 million to PBS and Repatriation Pharmaceutical Benefits Scheme expenditure between 2007-08 and 2010-11.